Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 34 Leiomyoma 12 Menorrhagia 5 Endometriosis 4 Myofibroma 3 Prostate Adenocarcinoma 2 Pregnancy Complications 2 Adenocarcinoma 2 Uterine Neoplasms 1 Uterine Hemorrhage 1 Pathologic Complete Response 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Myoma 1 Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1 Metastatic Castration-Resistant Prostate Cancer 1 Hormone Treatment-naïve Participants With Prostate Cancer 1

Interventions

pembrolizumab 156 Gemcitabine 140 Capecitabine 123 Paclitaxel 120 Fluorouracil 117 Oxaliplatin 110 Bevacizumab 106 Nivolumab 99 Leucovorin 97 Docetaxel 97 Cisplatin 89 Radiosurgery 88 Irinotecan 87 Carboplatin 85 Cetuximab 72 Cyclophosphamide 71 Magnetic Resonance Spectroscopy 68 Specimen Handling 60 Radiotherapy 60 Trastuzumab 59 Biopsy 59 Ipilimumab 53 Drug Therapy 51 Everolimus 48 Pemetrexed 46 Albumin-Bound Paclitaxel 45 130-nm albumin-bound paclitaxel 44 Doxorubicin 42 Fulvestrant 40 aldesleukin 37

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm Metastasis × relugolix × Clear all

NCT04787744 2026-04-08

VA STARPORT

VA Office of Research and Development

Phase 2/3 Recruiting

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡